Loading…
Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children
Two doses of a varicella-containing vaccine in healthy children
Saved in:
| Published in: | European journal of pediatrics 2012-03, Vol.171 (3), p.463-470 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c434t-c37e6209455b8187ee5a3d4085c76ed97d7c16ea5e2768cb5bd3bf04374c26703 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c434t-c37e6209455b8187ee5a3d4085c76ed97d7c16ea5e2768cb5bd3bf04374c26703 |
| container_end_page | 470 |
| container_issue | 3 |
| container_start_page | 463 |
| container_title | European journal of pediatrics |
| container_volume | 171 |
| creator | Knuf, Markus Zepp, Fred Helm, Klaus Maurer, Hartwig Prieler, Albrecht Kieninger-Baum, Dorothee Douha, Martine Willems, Paul |
| description | Two doses of a varicella-containing vaccine in healthy children |
| doi_str_mv | 10.1007/s00431-011-1569-4 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_923579609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>923579609</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-c37e6209455b8187ee5a3d4085c76ed97d7c16ea5e2768cb5bd3bf04374c26703</originalsourceid><addsrcrecordid>eNp9kU1uFDEQhS1ERIbAAdggSwjBpsFu_7WXUcRPpEhsYN1yu6szjtz2YHdPNLusuAAX4CwchZPgzkwAIcGqyvL3XpX9EHpCyStKiHqdCeGMVoTSigqpK34PrShndUWJkvfRijBOKkm1PkYPc74iRaNp8wAd11QzIRq-Ql9Ow-S62O_wBlJ2eYJgAQ8xYfb92w5MyuXgfbx24RJP1xH3MUPGccATTMlsjYcw4RFM9pB_3Hwd53Gz1DR34L0p3dYkZ5ceb421LgB2Aa_B-Gm9w3btfJ8gPEJHg_EZHh_qCfr09s3Hs_fVxYd352enF5XljE-VZQpkTTQXomtoowCEYT0njbBKQq9VryyVYATUSja2E13PuqF8kuK2loqwE_Ri77tJ8fMMeWpHl2-3CxDn3OqaCaUl0YV8-V-S0lrUTDG6mD77C72KcwrlHS0lWggtG80LRfeUTTHnBEO7SW40aVegdomz3cfZljjbJc520Tw9OM_dCP0vxV1-BXh-AEy2xg_JBOvyb65AuuGicPWey-UqXEL6c8V_Tf8JgIy8gg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1095596894</pqid></control><display><type>article</type><title>Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children</title><source>Springer Nature</source><creator>Knuf, Markus ; Zepp, Fred ; Helm, Klaus ; Maurer, Hartwig ; Prieler, Albrecht ; Kieninger-Baum, Dorothee ; Douha, Martine ; Willems, Paul</creator><creatorcontrib>Knuf, Markus ; Zepp, Fred ; Helm, Klaus ; Maurer, Hartwig ; Prieler, Albrecht ; Kieninger-Baum, Dorothee ; Douha, Martine ; Willems, Paul</creatorcontrib><description>Two doses of a varicella-containing vaccine in healthy children <12 years are suggested to induce better protection than a single dose. Persistence of immunity against measles, mumps, rubella, and varicella as well as varicella breakthrough cases were assessed 3 years after two-dose measles, mumps, rubella, and varicella (MMRV) vaccination or concomitant MMR (Priorix™) and varicella (Varilrix™) vaccination. Four hundred ninety-four healthy children, 12–18 months old at the time of the first dose, received either two doses of MMRV vaccine (GlaxoSmithKline Biologicals) 42–56 days apart (MMRV,
N
= 371) or one dose of MMR and varicella vaccines administered simultaneously at separate sites, followed by another MMR vaccination 42–56 days later (MMR + V,
N
= 123). Three hundred-four subjects participated in 3-year follow-up for persistence of immunity and occurrence of breakthrough varicella (MMRV,
N
= 225; MMR + V,
N
= 79). Antibodies were measured by ELISA (measles, mumps, rubella) and immunofluorescence (varicella). Contacts with individuals with varicella or zoster and cases of breakthrough varicella disease were recorded. Three years post-vaccination seropositivity rates in subjects seronegative before vaccination were: MMRV-measles, 98.5% (geometric mean titer [GMT] = 3,599.6); mumps, 97.4% (GMT = 1,754.5); rubella, 100% (GMT = 51.9); varicella, 99.4% (GMT = 225.5); MMR + V-measles, 97.0% (GMT = 1,818.8); mumps, 93.8% (GMT = 1,454.6); rubella, 100% (GMT = 53.8); and varicella, 96.8% (GMT = 105.8). Of the subjects, 15–20% reported contact with individuals with varicella/zoster each year. After 3 years, the cumulative varicella breakthrough disease rate was 0.7% (two cases) in the MMRV group and 5.4% (five cases) in the MMR + V group.
Conclusion
: Immunogenicity of the combined MMRV vaccine was sustained 3 years post-vaccination. (208136/041/NCT00406211).</description><identifier>ISSN: 0340-6199</identifier><identifier>EISSN: 1432-1076</identifier><identifier>DOI: 10.1007/s00431-011-1569-4</identifier><identifier>PMID: 21935584</identifier><identifier>CODEN: EJPEDT</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Antibodies ; Antibodies, Viral - blood ; Biological and medical sciences ; Chicken pox ; Chickenpox - immunology ; Chickenpox Vaccine - administration & dosage ; Chickenpox Vaccine - immunology ; Child, Preschool ; Children ; Combined vaccines ; Enzyme-Linked Immunosorbent Assay ; Fluorescent Antibody Technique, Indirect ; Follow-Up Studies ; General aspects ; Herpesvirus 3, Human - immunology ; Human viral diseases ; Humans ; Immunity ; Immunization Schedule ; Immunofluorescence ; Immunogenicity ; Infant ; Infectious diseases ; Measles ; Measles - immunology ; Measles virus - immunology ; Measles-Mumps-Rubella Vaccine - administration & dosage ; Measles-Mumps-Rubella Vaccine - immunology ; Medical sciences ; Medicine ; Medicine & Public Health ; Mumps ; Mumps - immunology ; Mumps virus - immunology ; Original Paper ; Pediatrics ; Rubella ; Rubella - immunology ; Rubella virus - immunology ; Vaccination ; Vaccines ; Vaccines, Combined ; Varicella ; Viral diseases ; Viral diseases of the respiratory system and ent viral diseases ; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><ispartof>European journal of pediatrics, 2012-03, Vol.171 (3), p.463-470</ispartof><rights>Springer-Verlag 2011</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-c37e6209455b8187ee5a3d4085c76ed97d7c16ea5e2768cb5bd3bf04374c26703</citedby><cites>FETCH-LOGICAL-c434t-c37e6209455b8187ee5a3d4085c76ed97d7c16ea5e2768cb5bd3bf04374c26703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25589845$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21935584$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knuf, Markus</creatorcontrib><creatorcontrib>Zepp, Fred</creatorcontrib><creatorcontrib>Helm, Klaus</creatorcontrib><creatorcontrib>Maurer, Hartwig</creatorcontrib><creatorcontrib>Prieler, Albrecht</creatorcontrib><creatorcontrib>Kieninger-Baum, Dorothee</creatorcontrib><creatorcontrib>Douha, Martine</creatorcontrib><creatorcontrib>Willems, Paul</creatorcontrib><title>Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children</title><title>European journal of pediatrics</title><addtitle>Eur J Pediatr</addtitle><addtitle>Eur J Pediatr</addtitle><description>Two doses of a varicella-containing vaccine in healthy children <12 years are suggested to induce better protection than a single dose. Persistence of immunity against measles, mumps, rubella, and varicella as well as varicella breakthrough cases were assessed 3 years after two-dose measles, mumps, rubella, and varicella (MMRV) vaccination or concomitant MMR (Priorix™) and varicella (Varilrix™) vaccination. Four hundred ninety-four healthy children, 12–18 months old at the time of the first dose, received either two doses of MMRV vaccine (GlaxoSmithKline Biologicals) 42–56 days apart (MMRV,
N
= 371) or one dose of MMR and varicella vaccines administered simultaneously at separate sites, followed by another MMR vaccination 42–56 days later (MMR + V,
N
= 123). Three hundred-four subjects participated in 3-year follow-up for persistence of immunity and occurrence of breakthrough varicella (MMRV,
N
= 225; MMR + V,
N
= 79). Antibodies were measured by ELISA (measles, mumps, rubella) and immunofluorescence (varicella). Contacts with individuals with varicella or zoster and cases of breakthrough varicella disease were recorded. Three years post-vaccination seropositivity rates in subjects seronegative before vaccination were: MMRV-measles, 98.5% (geometric mean titer [GMT] = 3,599.6); mumps, 97.4% (GMT = 1,754.5); rubella, 100% (GMT = 51.9); varicella, 99.4% (GMT = 225.5); MMR + V-measles, 97.0% (GMT = 1,818.8); mumps, 93.8% (GMT = 1,454.6); rubella, 100% (GMT = 53.8); and varicella, 96.8% (GMT = 105.8). Of the subjects, 15–20% reported contact with individuals with varicella/zoster each year. After 3 years, the cumulative varicella breakthrough disease rate was 0.7% (two cases) in the MMRV group and 5.4% (five cases) in the MMR + V group.
Conclusion
: Immunogenicity of the combined MMRV vaccine was sustained 3 years post-vaccination. (208136/041/NCT00406211).</description><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Biological and medical sciences</subject><subject>Chicken pox</subject><subject>Chickenpox - immunology</subject><subject>Chickenpox Vaccine - administration & dosage</subject><subject>Chickenpox Vaccine - immunology</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Combined vaccines</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Fluorescent Antibody Technique, Indirect</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Herpesvirus 3, Human - immunology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunization Schedule</subject><subject>Immunofluorescence</subject><subject>Immunogenicity</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Measles</subject><subject>Measles - immunology</subject><subject>Measles virus - immunology</subject><subject>Measles-Mumps-Rubella Vaccine - administration & dosage</subject><subject>Measles-Mumps-Rubella Vaccine - immunology</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mumps</subject><subject>Mumps - immunology</subject><subject>Mumps virus - immunology</subject><subject>Original Paper</subject><subject>Pediatrics</subject><subject>Rubella</subject><subject>Rubella - immunology</subject><subject>Rubella virus - immunology</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, Combined</subject><subject>Varicella</subject><subject>Viral diseases</subject><subject>Viral diseases of the respiratory system and ent viral diseases</subject><subject>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><issn>0340-6199</issn><issn>1432-1076</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kU1uFDEQhS1ERIbAAdggSwjBpsFu_7WXUcRPpEhsYN1yu6szjtz2YHdPNLusuAAX4CwchZPgzkwAIcGqyvL3XpX9EHpCyStKiHqdCeGMVoTSigqpK34PrShndUWJkvfRijBOKkm1PkYPc74iRaNp8wAd11QzIRq-Ql9Ow-S62O_wBlJ2eYJgAQ8xYfb92w5MyuXgfbx24RJP1xH3MUPGccATTMlsjYcw4RFM9pB_3Hwd53Gz1DR34L0p3dYkZ5ceb421LgB2Aa_B-Gm9w3btfJ8gPEJHg_EZHh_qCfr09s3Hs_fVxYd352enF5XljE-VZQpkTTQXomtoowCEYT0njbBKQq9VryyVYATUSja2E13PuqF8kuK2loqwE_Ri77tJ8fMMeWpHl2-3CxDn3OqaCaUl0YV8-V-S0lrUTDG6mD77C72KcwrlHS0lWggtG80LRfeUTTHnBEO7SW40aVegdomz3cfZljjbJc520Tw9OM_dCP0vxV1-BXh-AEy2xg_JBOvyb65AuuGicPWey-UqXEL6c8V_Tf8JgIy8gg</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Knuf, Markus</creator><creator>Zepp, Fred</creator><creator>Helm, Klaus</creator><creator>Maurer, Hartwig</creator><creator>Prieler, Albrecht</creator><creator>Kieninger-Baum, Dorothee</creator><creator>Douha, Martine</creator><creator>Willems, Paul</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20120301</creationdate><title>Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children</title><author>Knuf, Markus ; Zepp, Fred ; Helm, Klaus ; Maurer, Hartwig ; Prieler, Albrecht ; Kieninger-Baum, Dorothee ; Douha, Martine ; Willems, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-c37e6209455b8187ee5a3d4085c76ed97d7c16ea5e2768cb5bd3bf04374c26703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Biological and medical sciences</topic><topic>Chicken pox</topic><topic>Chickenpox - immunology</topic><topic>Chickenpox Vaccine - administration & dosage</topic><topic>Chickenpox Vaccine - immunology</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Combined vaccines</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Fluorescent Antibody Technique, Indirect</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Herpesvirus 3, Human - immunology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunization Schedule</topic><topic>Immunofluorescence</topic><topic>Immunogenicity</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Measles</topic><topic>Measles - immunology</topic><topic>Measles virus - immunology</topic><topic>Measles-Mumps-Rubella Vaccine - administration & dosage</topic><topic>Measles-Mumps-Rubella Vaccine - immunology</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mumps</topic><topic>Mumps - immunology</topic><topic>Mumps virus - immunology</topic><topic>Original Paper</topic><topic>Pediatrics</topic><topic>Rubella</topic><topic>Rubella - immunology</topic><topic>Rubella virus - immunology</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, Combined</topic><topic>Varicella</topic><topic>Viral diseases</topic><topic>Viral diseases of the respiratory system and ent viral diseases</topic><topic>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knuf, Markus</creatorcontrib><creatorcontrib>Zepp, Fred</creatorcontrib><creatorcontrib>Helm, Klaus</creatorcontrib><creatorcontrib>Maurer, Hartwig</creatorcontrib><creatorcontrib>Prieler, Albrecht</creatorcontrib><creatorcontrib>Kieninger-Baum, Dorothee</creatorcontrib><creatorcontrib>Douha, Martine</creatorcontrib><creatorcontrib>Willems, Paul</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knuf, Markus</au><au>Zepp, Fred</au><au>Helm, Klaus</au><au>Maurer, Hartwig</au><au>Prieler, Albrecht</au><au>Kieninger-Baum, Dorothee</au><au>Douha, Martine</au><au>Willems, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children</atitle><jtitle>European journal of pediatrics</jtitle><stitle>Eur J Pediatr</stitle><addtitle>Eur J Pediatr</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>171</volume><issue>3</issue><spage>463</spage><epage>470</epage><pages>463-470</pages><issn>0340-6199</issn><eissn>1432-1076</eissn><coden>EJPEDT</coden><abstract>Two doses of a varicella-containing vaccine in healthy children <12 years are suggested to induce better protection than a single dose. Persistence of immunity against measles, mumps, rubella, and varicella as well as varicella breakthrough cases were assessed 3 years after two-dose measles, mumps, rubella, and varicella (MMRV) vaccination or concomitant MMR (Priorix™) and varicella (Varilrix™) vaccination. Four hundred ninety-four healthy children, 12–18 months old at the time of the first dose, received either two doses of MMRV vaccine (GlaxoSmithKline Biologicals) 42–56 days apart (MMRV,
N
= 371) or one dose of MMR and varicella vaccines administered simultaneously at separate sites, followed by another MMR vaccination 42–56 days later (MMR + V,
N
= 123). Three hundred-four subjects participated in 3-year follow-up for persistence of immunity and occurrence of breakthrough varicella (MMRV,
N
= 225; MMR + V,
N
= 79). Antibodies were measured by ELISA (measles, mumps, rubella) and immunofluorescence (varicella). Contacts with individuals with varicella or zoster and cases of breakthrough varicella disease were recorded. Three years post-vaccination seropositivity rates in subjects seronegative before vaccination were: MMRV-measles, 98.5% (geometric mean titer [GMT] = 3,599.6); mumps, 97.4% (GMT = 1,754.5); rubella, 100% (GMT = 51.9); varicella, 99.4% (GMT = 225.5); MMR + V-measles, 97.0% (GMT = 1,818.8); mumps, 93.8% (GMT = 1,454.6); rubella, 100% (GMT = 53.8); and varicella, 96.8% (GMT = 105.8). Of the subjects, 15–20% reported contact with individuals with varicella/zoster each year. After 3 years, the cumulative varicella breakthrough disease rate was 0.7% (two cases) in the MMRV group and 5.4% (five cases) in the MMR + V group.
Conclusion
: Immunogenicity of the combined MMRV vaccine was sustained 3 years post-vaccination. (208136/041/NCT00406211).</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>21935584</pmid><doi>10.1007/s00431-011-1569-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-6199 |
| ispartof | European journal of pediatrics, 2012-03, Vol.171 (3), p.463-470 |
| issn | 0340-6199 1432-1076 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_923579609 |
| source | Springer Nature |
| subjects | Antibodies Antibodies, Viral - blood Biological and medical sciences Chicken pox Chickenpox - immunology Chickenpox Vaccine - administration & dosage Chickenpox Vaccine - immunology Child, Preschool Children Combined vaccines Enzyme-Linked Immunosorbent Assay Fluorescent Antibody Technique, Indirect Follow-Up Studies General aspects Herpesvirus 3, Human - immunology Human viral diseases Humans Immunity Immunization Schedule Immunofluorescence Immunogenicity Infant Infectious diseases Measles Measles - immunology Measles virus - immunology Measles-Mumps-Rubella Vaccine - administration & dosage Measles-Mumps-Rubella Vaccine - immunology Medical sciences Medicine Medicine & Public Health Mumps Mumps - immunology Mumps virus - immunology Original Paper Pediatrics Rubella Rubella - immunology Rubella virus - immunology Vaccination Vaccines Vaccines, Combined Varicella Viral diseases Viral diseases of the respiratory system and ent viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye |
| title | Antibody persistence for 3 years following two doses of tetravalent measles–mumps–rubella–varicella vaccine in healthy children |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A23%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20persistence%20for%203%C2%A0years%20following%20two%20doses%20of%20tetravalent%20measles%E2%80%93mumps%E2%80%93rubella%E2%80%93varicella%20vaccine%20in%20healthy%20children&rft.jtitle=European%20journal%20of%20pediatrics&rft.au=Knuf,%20Markus&rft.date=2012-03-01&rft.volume=171&rft.issue=3&rft.spage=463&rft.epage=470&rft.pages=463-470&rft.issn=0340-6199&rft.eissn=1432-1076&rft.coden=EJPEDT&rft_id=info:doi/10.1007/s00431-011-1569-4&rft_dat=%3Cproquest_cross%3E923579609%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c434t-c37e6209455b8187ee5a3d4085c76ed97d7c16ea5e2768cb5bd3bf04374c26703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1095596894&rft_id=info:pmid/21935584&rfr_iscdi=true |